Stock ATYR ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings aTyr Pharma, Inc.

Equities

ATYR

US0021202025

Real-time Estimate Cboe BZX
Other stock markets
 14:15:53 2024-06-26 EDT 		5-day change 1st Jan Change
1.535 USD +5.14% Intraday chart for aTyr Pharma, Inc. -2.53% +9.22%
06-05 ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE CI
05-14 ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ATYR PHARMA, INC. Stock aTyr Pharma, Inc.
+9.22% 101M -
MODERNA, INC. Stock Moderna, Inc.
+24.17% 52.73B
B-
LONZA GROUP AG Stock Lonza Group AG
+37.49% 39B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.34% 38.52B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.46% 30.38B
B
CELLTRION, INC. Stock Celltrion, Inc.
-12.26% 26.39B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.31% 26.08B
B-
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.97% 14.15B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.45% 12.6B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-5.72% 11.51B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ATYR Stock
  4. Ratings aTyr Pharma, Inc.